|
Anti-VEGF monoclonal antibody
|
Indications for use
|
| Bevacizumab |
Metastatic colorectal cancer |
| Non-small-cell lung cancer |
| Glioblastoma multiforme |
| Metastatic renal cell cancer |
| Macular degeneration |
| Metastatic HER2 negative breast cancer |
| Persistent, recurrent, and metastatic cervical cancer |
| Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer |
|
|
VEGF decoy receptor (VEGF-Trap)
|
Indications for use
|
| Aflibercept |
Metastatic colorectal cancer |
|
|
Tyrosine kinase inhibitors
|
Indications for use
|
| Sorafenib |
Metastatic renal cell cancer |
| Hepatic cancer (hepatocellular carcinoma) |
| Sunitinib |
Metastatic renal cell carcinoma |
| Gastrointestinal stromal tumour |
| Pancreatic neuroendocrine tumour |
| Cabozantinib |
Medullary thyroid cancer |
| Erlotinib |
Non-small-cell lung cancer |
| Pancreatic cancer |
| Axitinib |
Metastatic renal cell cancer |
| Pegaptanib |
Macular degeneration |
| Ranibizumab |
Macular degeneration |
| Pazopanib |
Metastatic renal cell cancer |
| Soft tissue sarcoma |
| Vandetanib |
Medullary thyroid cancer |
| Regorafenib |
Metastatic colorectal cancer |
| Gastrointestinal stromal tumour |
| Imatinib |
Chronic myeloid leukemia |
| Renal cell cancer |
| Gastrointestinal stromal tumour |
| Dasatinib |
Philadelphia chromosome-positive (Ph+) chronic |
| myeloid leukemia (CML) |
| Chronic phase Ph+ CML |
| Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (Ph+ ALL) |
|
|
Mammalian target of rapamycin inhibitors (mTOR inhibitors)
|
Indications for use
|
| Temsirolimus |
Renal cell cancer |
| Everolimus |
Advanced breast cancer |
| Advanced renal cell cancer |
| Pancreatic neuroendocrine tumour |
| Tuberous sclerosis complex |
| Subependymal giant cell astrocytoma |
